Stocks
ETFs & Funds
Bonds & Rates
Commodities
Cryptocurrency
Forex
Earnings
U.S.
Tech
China
Fed
Economy
Inflation
Bitcoin (BTC)
Nasdaq 100
Business
Energy
Wall Street
Dividend
NYSE
Tesla (TSLA)
Apple (AAPL)
U.K.
SEC
IPOs
Gold
NVIDIA (NVDA)
Money
S&P 500
Ethereum (ETH)
Europe
Japan
Blockchain
EUR USD
Amazon (AMZN)
Ripple (XRP)
Investing
Dow Jones
Microsoft (MSFT)
Taxes
Meta Platforms (META)
GBP USD
Retirement
Walt Disney (DIS)
Health
Natural Gas
Elon Musk
Cars
Google
Binance
Finance
Australia
Stablecoins
Ford Motor (F)
Goldman Sachs (GS)
Options
Coinbase
USD JPY
Crude Oil
Real Estate
AUD USD
Asia
Morgan Stanley (MS)
XAU USD
Banking
Canada
NFT
REITs
Wealth
Manufacturing
Twitter (TWTR)
Mining
Coronavirus
Netflix (NFLX)
USD CAD
Insurance
JPMorgan (JPM)
Silver
Dollar Index
PayPal (PYPL)
Economics
Solana (SOL)
NZD USD
DeFi
FOMC
Germany
Loans
Intel (INTC)
Environment
Walmart (WMT)
Bank of America (BAC)
Polygon (MATIC)
Wells Fargo&Co (WFC)
Shiba Inu (SHIB)
EUR GBP
Steel
Alibaba (BABA)
AT&T (T)
WTI
EUR JPY
Dogecoin (DOGE)
Boeing (BA)
France
Donald Trump
USD CHF
BlackRock (BLK)
More +
Stock Market News
BioMarin: More Growth Is Coming
Seeking Alpha
Biomarin Pharma (BMRN)
2 months
Are Gene Therapy Stocks The Market’s Next Big Winners?
MarketBeat
24 hours
BioMarin’s share prices fluctuate following Phase 3 clinical trial results
Investing.com
1 week
BioMarin: Q2 2023 Confirmed My Bullish View
Seeking Alpha
2 months
Biomarin Pharmaceutical, Inc. (BMRN) Q2 2023 Earnings Call Transcript
Seeking Alpha
2 months
Biomarin Pharma earnings beat by $0.31, revenue topped estimates
Investing.com
2 months
Read more news +